OSE Immunotherapeutics Expands Program Around Lusvertikimab
OSE Immunotherapeutics announces the selection of two new clinical indications for lusvertikimab (OSE-127): chronic pouchitis and hidradenitis suppurativa. This decision is part of the Company's 2026-2028 strategic plan, aimed at expanding the use of the drug candidate for targeted autoimmune diseases.
Strategic Expansion into New Indications
Chronic pouchitis and hidradenitis suppurativa were chosen due to their biological rationale with IL-7R, the target of lusvertikimab. These two indications are part of the 2026-2028 strategic plan aimed at expanding the use of lusvertikimab for targeted autoimmune diseases. The Company aims for a balanced diversification strategy: chronic pouchitis as a short-term rare disease, hidradenitis suppurativa in dermatology in the medium term, complemented by the existing program in ulcerative colitis.
Initiation of Clinical Trials and Partnership Plans
The start of a first Phase 2 clinical trial is scheduled for the second half of 2026, subject to funding. Concurrently, OSE will transition its ulcerative colitis indication to a subcutaneous formulation of lusvertikimab and aims to establish a partnership once bioequivalence data are obtained. Additional scientific data will be generated to validate a potentially predictive biomarker identified in the Phase 2 CoTikiS study.
